European principles of inhibitor management in patients with haemophilia: implications of new treatment options | Orphanet Journal of Rare Diseases | Full Text

European principles of inhibitor management in patients with haemophilia: implications of new treatment options | Orphanet Journal of Rare Diseases | Full Text

European principles of inhibitor management in patients with haemophilia: implications of new treatment options

• C. Hermans, 
• P. L. F. Giangrande, 
• B. O’Mahony, 
• P. de Kleijn, 
• M. Bedford, 
• A. Batorova, 
• J. Blatný, 
• K. Jansone & 
• on behalf of the European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD)

Orphanet Journal of Rare Diseases volume 15, Article number: 219 (2020) Cite this article

• Metricsdetails

In light of the rapidly changing landscape of haemophilia treatment, the authors of the position paper on the “European Principles of Inhibitor Management” published in 2018 (Table 1) [1] now provide an update on the major impact of novel therapies that bypass and/or substitute clotting factor VIII (FVIII) and IX (FIX) in the care of haemophilia patients with FVIII- or FIX-neutralizing allo-inhibitory antibodies (inhibitors).